Nab-paclitaxel trials for Lung cancer

All Nab-paclitaxel trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Nab-paclitaxel for Lung cancer

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 325 locations
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  NCT06996782 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 103 locations
• A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
  NCT06421298 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 57 locations
• A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
  NCT07221474 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
  NCT06731907 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
  NCT07063745 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 320 locations
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
  NCT06096844 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 324 locations
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
  NCT05800587 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
  NCT05766800 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
  NCT04892953 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
  NCT05800340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
  NCT05786924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
  NCT04253964 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Second-line Immunotherapy for ES-SCLC
  NCT06853678 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
  NCT05501665 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
  NCT05624996 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 477 locations

Common questions

How many trials study Nab-paclitaxel for Lung cancer?

22 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.